摘要
右佐匹克隆是一种非苯二氮卓类镇静催眠药,通过异构性调控GABA受体发挥镇静催眠作用,是佐匹克隆的S异构体,但对中枢苯二氮卓类受体的亲和性比佐匹克隆强50倍,不良反应和毒性更小。右佐匹克隆于2004年获得美国FDA批准用于治疗睡眠障碍。近年来,随着临床应用的普及,相关的临床研究数据也在不断更新,临床上发现其不仅可用于治疗原发性失眠,还可用于呼吸睡眠暂停、抑郁症、创伤后应激障碍、围绝经期等伴随的共病性失眠。因此,本文就右佐匹克隆近十余年来的临床研究进展进行综述。
Eszopiclone is a non-benzodiazepine sedative and hypnotic agent,which plays a sedative and hypnotic effects by regulating GABA receptor through isomerism,with the affinity to the central benzodiazepine receptor in about 50 times stronger than zopiclone,with less adverse reaction and toxicity.Eszopiclone has been approved by Food and Drug Administration(FDA)of United States for the treatment of insomnia in 2004.In recent years,with the popularization of clinical application,relevant clinical research data are constantly updated.In clinical practice,it could be used not only for primary insomnia,but also for the comorbid insomnia accompanied by sleep apnea syndrome,depression,post-traumatic stress disorder,perimenopausal and postmenopausal women.It is worthy to take a brief review on the clinical literatures of eszopiclone in order to provide a updated introduction for the clinicians.
作者
贾敏
黄金莎
刘群会
王涛
JIA Min;HUANG Jinsha;LIU Qunhui;WANG Tao(Department of Neurology, the Central Hospital of Enshi Tujia and Miao Autonomous Prefectures, Enshi 445000, Hubei, China;Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2019年第11期1300-1304,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家重点研发计划(2017YFC1310200)
国家自然科学基金(81671260,81974201)
关键词
右佐匹克隆
镇静催眠
失眠
eszopiclone
sedative hypnotics
insomnia
